Axsome Therapeutics (NASDAQ:AXSM) COO Mark Jacobson Sells 4,517 Shares of Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) COO Mark Jacobson sold 4,517 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $227.94, for a total transaction of $1,029,604.98. Following the transaction, the chief operating officer owned 4,517 shares in the company, valued at approximately $1,029,604.98. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Axsome Therapeutics Stock Down 0.3%

Shares of NASDAQ AXSM opened at $223.06 on Wednesday. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.55 and a quick ratio of 1.48. The company has a 50-day moving average price of $171.73 and a 200-day moving average price of $163.34. The stock has a market capitalization of $11.47 billion, a P/E ratio of -59.80 and a beta of 0.59. Axsome Therapeutics, Inc. has a 1 year low of $96.09 and a 1 year high of $234.29.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). Axsome Therapeutics had a negative return on equity of 246.90% and a negative net margin of 26.59%.The business had revenue of $191.20 million during the quarter, compared to analyst estimates of $191.10 million. The business’s revenue was up 57.4% on a year-over-year basis. On average, equities research analysts forecast that Axsome Therapeutics, Inc. will post -1.05 EPS for the current fiscal year.

More Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Very strong top-line growth — 1Q net product revenue of $191.2M, up ~57% YoY, driven by AUVELITY ($153.2M) and SUNOSI ($33.9M); this validates commercial traction for Axsome’s lead products. Axsome 1Q 2026 Financial Results
• Positive Sentiment: Multiple analyst price-target lifts today (notably Mizuho to $310, Wells Fargo to $255, Baird to $246, Morgan Stanley to $242) and continued “buy/outperform” coverage increase perceived upside and support near-term sentiment. Analyst Coverage & Price Target Moves
• Positive Sentiment: Pipeline and corporate catalysts remain in play — AUVELITY approval for agitation in Alzheimer’s, NDA submission for AXS?12 (cataplexy), addition of AXS?20 to the pipeline — these can drive medium/long-term upside. Business Update & Pipeline Highlights
• Neutral Sentiment: Management outreach: Axsome will participate in multiple investor conferences (BofA fireside chat, others) — useful for additional disclosure but timing/impact is uncertain. Investor Conference Participation
• Neutral Sentiment: Full earnings and call transcripts are available for deeper read-throughs; analysts and commentators are parsing sequential trends and guidance in detail. Earnings Call Transcript & Analysis
• Negative Sentiment: Earnings miss: GAAP EPS of ($1.26) vs. consensus (~$0.85 loss) — the wider loss and negative margins/ROE raise near-term profitability concerns despite revenue strength. Q1 Loss Widens; Revenues Jump (Zacks)
• Negative Sentiment: Some skepticism on sustainability — commentary notes sequential sales dips for key products and questions about achievability of management’s long?term peak revenue targets, which could temper enthusiasm. Earnings Review & Skepticism (Seeking Alpha)

Institutional Investors Weigh In On Axsome Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Versant Capital Management Inc increased its stake in shares of Axsome Therapeutics by 20,300.0% in the third quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock worth $25,000 after purchasing an additional 203 shares in the last quarter. Kemnay Advisory Services Inc. bought a new position in Axsome Therapeutics in the 4th quarter worth approximately $31,000. First Horizon Corp bought a new position in Axsome Therapeutics in the 3rd quarter worth approximately $34,000. Optiver Holding B.V. grew its stake in Axsome Therapeutics by 82.3% in the 3rd quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock valued at $35,000 after buying an additional 130 shares in the last quarter. Finally, Ameriflex Group Inc. bought a new stake in Axsome Therapeutics during the 4th quarter valued at $37,000. 81.49% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Monday, April 20th. Deutsche Bank Aktiengesellschaft set a $280.00 target price on shares of Axsome Therapeutics in a report on Tuesday. Royal Bank Of Canada boosted their price objective on Axsome Therapeutics from $242.00 to $302.00 and gave the stock an “outperform” rating in a research report on Tuesday. TD Cowen reissued a “buy” rating on shares of Axsome Therapeutics in a research report on Friday. Finally, HC Wainwright set a $290.00 price target on shares of Axsome Therapeutics in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $251.89.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.